Top

Acta Diabetologica

Published in:

01-10-2018 | Original Article

The effects of probiotics and synbiotic supplementation on glucose and insulin metabolism in adults with prediabetes: a double-blind randomized clinical trial

Authors: Nazila Kassaian, Awat Feizi, Ashraf Aminorroaya, Parvaneh Jafari, Maryam Tajabadi Ebrahimi, Masoud Amini

Published in: Acta Diabetologica | Issue 10/2018

Abstract

Aims

Probiotics and/or prebiotics could be a promising approach to improve metabolic disorders by favorably modifying the gut microbial composition.

Objectives

To assess the effects of probiotics and synbiotic on glycemic indices in prediabetic individuals who are at risk of type 2 diabetes and its complications.

Methods

In a double-blind, randomized, placebo-controlled parallel-group clinical trial, 120 prediabetic adults participated and were randomly allocated to receive either probiotics or synbiotic or placebo supplements for 24 weeks. Anthropometric measurements, food record, physical activity and glycemic biomarkers including glycated hemoglobin (HbA1C), fasting plasma glucose (FPG), fasting insulin levels (FIL), homoeostasis model assessment for insulin resistance (HOMA-IR), quantitative insulin sensitivity check index (QUICKI), and β-cell function (HOMA-B) were assessed at baseline and repeated at 12 and 24 weeks and compared within and between three groups using repeated measure ANOVA.

Results

Compared with the placebo, synbiotic supplementation resulted in a higher significant reduction in FPG (− 6.5 ± 1.6 vs. − 0.82 ± 1.7 mg/dL, P = 0.01), FIL (− 2.6 ± 0.9 vs. − 0.8 ± 0.8 µIU/mL, P = 0.028), and HOMA-IR (− 0.86 ± 0.3 vs. − 0.16 ± 0.25, P = 0.007), and a significant elevation in the QUICKI (+ 0.01 ± 0.003 vs. + 0.003 ± 0.002, P = 0.006). In addition, significant decreases in HbA1C was seen following the supplementation of probiotics and synbiotic compared with the placebo (− 0.12 ± 0.06 and − 0.14 ± 0.05 vs. +0.07 ± 0.06%, P = 0.005 and 0.008, respectively). HOMA-B was not found to be different between or within the three groups.

Conclusion

Glycemic improvement by probiotics and particularly synbiotic supplements in prediabetic individuals has been supported by current study. However, further studies are required for optimal recommendations in this important area of patient treatment.

Trial registration

Iranian Registry of Clinical Trials: IRCT201511032321N2, Date registered February 27, 2016.

Rokana N, Duary RK, Panwar H, Batish VK, Grover S (2012) Management of metabolic syndrome through probiotic and prebiotic interventions. Indian J Endocrinol Metab 16(1):20–27CrossRefPubMedPubMedCentral

Daniele G, Abdul-Ghani M, DeFronzo RA (2014) What are the pharmacotherapy options for treating prediabetes? Expert Opin Pharmacother 15(14):2003–2018CrossRefPubMed

Bansal N (2015) Prediabetes diagnosis and treatment: a review. World J Diabetes 6(2):296–303CrossRefPubMedPubMedCentral

He M, Shi B (2017) Gut microbiota as a potential target of metabolic syndrome: the role of probiotics and prebiotics. Cell Biosci 7:54CrossRefPubMedPubMedCentral

Sato J, Kanazawa A, Watada H (2017) Type 2 diabetes and bacteremia. Ann Nutr Metab 71(Suppl 1):17–22CrossRefPubMed

Upadhyaya S, Banerjee G (2015) Type 2 diabetes and gut microbiome: at the intersection of known and unknown. Gut Microbes 6(2):85–92CrossRefPubMedPubMedCentral

Hulston CJ, Churnside AA, Venables MC (2015) Probiotic supplementation prevents high-fat, overfeeding-induced insulin resistance in human subjects. Br J Nutr 113(4):596–602CrossRefPubMedPubMedCentral

Sáez-Lara MJ, Robles-Sanchez C, Ruiz-Ojeda FJ, Plaza-Diaz J, Gil A (2016) Effects of probiotics and synbiotics on obesity, insulin resistance syndrome, type 2 diabetes and non-alcoholic fatty liver disease: a review of human clinical trials. Int J Mol Sci 17(6):928CrossRefPubMedCentral

Louis P, Flint HJ, Michel C (2016) How to manipulate the microbiota: prebiotics. Adv Exp Med Biol 902:119–142CrossRefPubMed

10.

de Vrese M, Schrezenmeir J (2008) Probiotics, prebiotics, and synbiotics. Adv Biochem Eng Biotechnol 111:1–66PubMed

11.

Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G et al (2016) The gut microbiota and host health: a new clinical frontier. Gut 65(2):330–339CrossRefPubMed

12.

Guiné RPF, Silva ACF (2017) Probiotics, Prebiotics and synbiotics. In: Nelson DL (ed) Functional foods: sources, health effects and future perspectives. Chapter 5. Nova Publishers, New York, 143–207

13.

Poppitt S (2017) Hyperglycaemia, pre-diabetes and diabesity: can we choose who to ‘fast-track’into diabetes prevention? Curr Res Diabetes Obes J 2(3):1–3

14.

Pandis N, Chung B, Scherrer R, Elbourne D, Altman D (2017) CONSORT extension for reporting within-person randomised trials. BMJ 357:1–22

15.

Eslamparast T, Zamani F, Hekmatdoost A, Sharafkhah M, Eghtesad S, Malekzadeh R et al (2014) Effects of synbiotic supplementation on insulin resistance in subjects with the metabolic syndrome: a randomised, double-blind, placebo-controlled pilot study. Br J Nutr 112(3):438–445CrossRefPubMed

16.

Matthews D, Hosker J, Rudenski A, Naylor B, Treacher D, Turner R (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419CrossRefPubMed

17.

Hřebíček J, Janout V, Malinčíková J, Horáková D, Čížek L (2002) Detection of insulin resistance by simple quantitative insulin sensitivity check index QUICKI for epidemiological assessment and prevention. J Clin Endocrinol Metab 87(1):144CrossRefPubMed

18.

Mossavar-Rahmani Y (2017) Reducing measurement error in nutrition assessment: potential research implications for Iran. Nutr Food Sci Res 4(1):3–10CrossRef

19.

Strath SJ, Kaminsky LA, Ainsworth BE, Ekelund U, Freedson PS, Gary RA et al (2013) Guide to the assessment of physical activity: clinical and research applications. Circulation 128(20):2259–2279CrossRefPubMed

20.

Yao K, Zeng L, He Q, Wang W, Lei J, Zou X (2017) Effect of probiotics on glucose and lipid metabolism in type 2 diabetes mellitus: a meta-analysis of 12 randomized controlled trials. Med Sci Monit 23:3044–3053CrossRefPubMedPubMedCentral

21.

Festi D, Schiumerini R, Eusebi LH, Marasco G, Taddia M, Colecchia A (2014) Gut microbiota and metabolic syndrome. World J Gastroenterol WJG 20(43):16079CrossRefPubMed

22.

Abrams SA, Griffin IJ, Hawthorne KM, Ellis KJ (2007) Effect of prebiotic supplementation and calcium intake on body mass index. J Pediatr 151(3):293–298CrossRefPubMed

23.

Pedersen C, Lefevre S, Peters V, Patterson M, Ghatei MA, Morgan LM et al (2013) Gut hormone release and appetite regulation in healthy non-obese participants following oligofructose intake. A dose-escalation study. Appetite 66:44–53CrossRefPubMed

24.

Franz MJ, VanWormer JJ, Crain AL, Boucher JL, Histon T, Caplan W et al (2007) Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc 107(10):1755–1767CrossRefPubMed

25.

Taghizadeh M, Asemi Z (2014) Effects of synbiotic food consumption on glycemic status and serum hs-CRP in pregnant women: a randomized controlled clinical trial. Hormones 13(3):398–406PubMed

26.

Tabrizi R, Moosazadeh M, Lankarani KB, Akbari M, Heydari ST, Kolahdooz F et al (2017) The effects of synbiotic supplementation on glucose metabolism and lipid profiles in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials. Probiot Antimicrob Proteins. https://doi.org/10.1007/s12602-017-9299-1 CrossRef

27.

Triplot N, Leber B, Blattl D (2012) Effect of supplementation with Lactobacillus casei Shirota on insulin sensitivity, b-cell function, and markers of endothelial function and inflammation in subjects with the metabolic syndrome—a pilot study. J Dairy Sci 96:89–95CrossRef

28.

Barazzoni R, Deutz N, Biolo G, Bischoff S, Boirie Y, Cederholm T et al (2017) Carbohydrates and insulin resistance in clinical nutrition: recommendations from the ESPEN expert group. Clin Nutr 36(2):355–363CrossRefPubMed

29.

Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D et al (2007) Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56(7):1761–1772CrossRefPubMed

30.

Allin KH, Nielsen T, Pedersen O (2015) Mechanisms in endocrinology: gut microbiota in patients with type 2 diabetes mellitus. Eur J Endocrinol 172(4):R167–R177CrossRefPubMed

31.

Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM et al (2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57(6):1470–1481CrossRefPubMed

32.

Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O et al(2009) Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 58(8):1091–1103CrossRefPubMed

33.

Gao Z, Yin J, Zhang J, Ward RE, Martin RJ, Lefevre M et al (2009) Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 58(7):1509–1517CrossRefPubMedPubMedCentral

34.

Lin HV, Frassetto A, Kowalik EJ Jr, Nawrocki AR, Lu MM, Kosinski JR et al (2012) Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PloS One 7(4):e35240CrossRefPubMedPubMedCentral

35.

Wichmann A, Allahyar A, Greiner TU, Plovier H, Lundén G, Larsson T et al (2013) Microbial modulation of energy availability in the colon regulates intestinal transit. Cell Host Microbe 14(5):582–590CrossRefPubMed

36.

Russo F, Riezzo G, Chiloiro M, De Michele G, Chimienti G, Marconi E et al (2010) Metabolic effects of a diet with inulin-enriched pasta in healthy young volunteers. Curr Pharm Des 16(7):825–831CrossRefPubMed

37.

Kim Y, Keogh J, Clifton P (2017) Probiotics, prebiotics, synbiotics and insulin sensitivity. Nutr Res Rev 17:1–17

38.

Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E et al (2012) Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61(2):364–371CrossRefPubMedPubMedCentral

Title: The effects of probiotics and synbiotic supplementation on glucose and insulin metabolism in adults with prediabetes: a double-blind randomized clinical trial
Authors: Nazila Kassaian
Awat Feizi
Ashraf Aminorroaya
Parvaneh Jafari
Maryam Tajabadi Ebrahimi
Masoud Amini
Publication date: 01-10-2018
Publisher: Springer Milan
Published in: Acta Diabetologica / Issue 10/2018
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-018-1175-2

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

The effects of probiotics and synbiotic supplementation on glucose and insulin metabolism in adults with prediabetes: a double-blind randomized clinical trial

Abstract

Aims

Objectives

Methods

Results

Conclusion

Trial registration

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Aims

Objectives

Methods

Results

Conclusion

Trial registration

Please log in to get access to this content

Other articles of this Issue 10/2018

Glucose regulation and physical performance among older people: the Helsinki Birth Cohort Study

FRAX tool in type 2 diabetic subjects: the use of HbA1c in estimating fracture risk

Fasting plasma glucose is a stronger predictor of diabetes than triglyceride–glucose index, triglycerides/high-density lipoprotein cholesterol, and homeostasis model assessment of insulin resistance: Tehran Lipid and Glucose Study

Correction to: The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial

Assessment of glucose effectiveness from short IVGTT in individuals with different degrees of glucose tolerance

Real-world use of self-monitoring of blood glucose in people with type 2 diabetes: an urgent need for improvement

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page